Omicron variant accelerates need for more diverse COVID-19 vaccine strategy
Current vaccines against SARS-CoV-2 that target the spike protein are an important step toward developing antiviral therapeutics and next-generation vaccines. These vaccines have reduced hospitalizations and deaths. However, as the virus continues to mutate and evolve, solely targeting the spike protein may not be enough for protective immunity.